...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of health economics >Early initiation of highly active antiretroviral therapies for AIDS: Dynamic choice with endogenous and exogenous learning
【24h】

Early initiation of highly active antiretroviral therapies for AIDS: Dynamic choice with endogenous and exogenous learning

机译：尽早开始针对艾滋病的高效抗逆转录病毒疗法：内源性和外源性学习的动态选择

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Criteria for initiation of highly active antiretroviral treatments (HAART) in HIV-infected patients remain a matter of debate world-wide because short-term benefits have to be balanced with costs of these therapies, and restrictions placed on future treatment options if resistant viral strains develop. On the other hand, postponing the introduction of HAART may involve a therapeutic opportunity cost if a patient's health is allowed to deteriorate to such an extent of becoming unable to benefit from new treatments currently under development when they become available. We introduce a two period model where period one treatment adoption is an irreversible act with future, but uncertain, consequences. New information, both endogenous and exogenous, arises over time and shapes the conditions surrounding the second period therapeutic decision. A surprising result is that, under conditions that appear close to those surrounding the HAART debate, the magnitude of the feared resistance effect has no effect on leaves the optimal treatment decision as far as it is high enough.
机译：HIV感染患者开始高活性抗逆转录病毒治疗（HAART）的标准仍然是全球争论的话题，因为短期利益必须与这些疗法的成本相平衡，并且如果耐药病毒株对未来治疗方案的限制发展。另一方面，如果允许患者的健康恶化到无法从当前正在开发的新疗法中受益的程度，则推迟引入HAART可能会带来治疗机会成本。我们引入了一个两阶段模型，其中第一阶段的治疗采用是不可逆转的行为，具有未来但不确定的后果。随着时间的流逝，内源性和外源性的新信息不断涌现，并形成了围绕第二期治疗决策的条件。令人惊讶的结果是，在看起来与HAART辩论有关的条件下，只要抗药性足够高，担心的抗药性效果就不会影响最佳治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号